NOT FOR DISTRIBUTION
Header cover image

Qinghai Spring Medicinal Resources Technology

Market Cap

CN¥3.5b

Last Updated

2021/04/17 09:03 UTC

Data Sources

Company Financials

Executive Summary

Qinghai Spring Medicinal Resources Technology Co., Ltd. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Qinghai Spring Medicinal Resources Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 600381 is more volatile than 90% of CN stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 600381's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.


Market Performance


7 Day Return

2.6%

600381

-2.8%

CN Pharmaceuticals

-0.8%

CN Market


1 Year Return

26.3%

600381

10.4%

CN Pharmaceuticals

25.0%

CN Market

Return vs Industry: 600381 exceeded the CN Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: 600381 exceeded the CN Market which returned 25% over the past year.


Shareholder returns

600381IndustryMarket
7 Day2.6%-2.8%-0.8%
30 Day-4.6%1.0%-0.08%
90 Day-11.6%-5.1%-5.3%
1 Year26.3%26.3%11.5%10.4%27.0%25.0%
3 Year-40.3%-40.3%25.2%20.8%29.1%22.8%
5 Yearn/a46.5%38.7%30.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is Qinghai Spring Medicinal Resources Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Qinghai Spring Medicinal Resources Technology undervalued compared to its fair value and its price relative to the market?

1.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 600381's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 600381's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 600381 is unprofitable, so we can't compare its PE Ratio to the CN Pharmaceuticals industry average.

PE vs Market: 600381 is unprofitable, so we can't compare its PE Ratio to the CN market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 600381's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 600381 is good value based on its PB Ratio (1.5x) compared to the CN Pharmaceuticals industry average (2.7x).


Future Growth

How is Qinghai Spring Medicinal Resources Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Qinghai Spring Medicinal Resources Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Qinghai Spring Medicinal Resources Technology performed over the past 5 years?

-45.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 600381 is currently unprofitable.

Growing Profit Margin: 600381 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 600381 is unprofitable, and losses have increased over the past 5 years at a rate of 45.6% per year.

Accelerating Growth: Unable to compare 600381's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 600381 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.3%).


Return on Equity

High ROE: 600381 has a negative Return on Equity (-3.02%), as it is currently unprofitable.


Financial Health

How is Qinghai Spring Medicinal Resources Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 600381's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥10.5M).

Long Term Liabilities: 600381's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥3.7M).


Debt to Equity History and Analysis

Debt Level: 600381 is debt free.

Reducing Debt: 600381 has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.

Debt Coverage: 600381 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 600381 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Qinghai Spring Medicinal Resources Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 600381's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 600381's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 600381's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 600381's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 600381's dividend in 3 years as they are not forecast to pay a notable one for the CN market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Qinghai Spring Medicinal Resources Technology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Qinghai Spring Medicinal Resources Technology Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Qinghai Spring Medicinal Resources Technology Co., Ltd.
  • Ticker: 600381
  • Exchange: SHSE
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥3.462b
  • Shares outstanding: 587.06m
  • Website: https://www.verygrass.com

Number of Employees


Location

  • Qinghai Spring Medicinal Resources Technology Co., Ltd.
  • Ningjing Business Center
  • 16th Floor
  • Xining
  • Qinghai Province
  • 810007
  • China

Listings


Biography

Qinghai Spring Medicinal Resources Technology Co., Ltd. explores and develops natural medicinal resources on the Qinghai-Tibet Plateau. It provides polar and Herborist grass 5X cordyceps sinensis series of...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 09:03
End of Day Share Price2021/04/16 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.